title: Multiple human papillomavirus infections and type-competition in women from a clinic attendee population in China.
abstract: To investigate the multi-infection patterns and type competition for human papillomavirus (HPV) in Chinese clinic attending women and evaluate the association between the infection status and cancer risk. Three hundred and thirty-two HPV-DNA-positive samples were genotyped for 21 HPVs and tested for 13 types of HPV neutralizing antibody using pseudoviron-based assay. Odds ratios (ORs) were calculated to evaluate the coinfection patterns for both DNA and neutralizing antibody (NAb), and the associations of HSIL+ with HPV DNA and NAb. Of the 332 HPV-DNA-positive subjects, 279 (84.0%) were detected as NAb positive. Multi-positive results were identified in 23.2% (77/332) HPV DNA tests and 60.2% (168/279) HPV NAb assays. The NAb titers for the multiple-positive samples (geometric mean 214) were significantly higher than the single-positive samples (geometric mean 114) (P < 0.01). HPV16-HPV52 was identified as a type-competition pair for both HPV DNA (OR = 0.09; 95%CI = 0.02-0.42) and NAb (OR = 0.27; 95%CI = 0.11-0.69) data. Compared to other types, HPV16 DNA was associated significantly with high risk of HSIL+ (OR = 2.57; 95%CI = 1.23-5.38). HPV16-HPV52 was identified as a potential type-competition pair, which might result in the type modulation with the implementation of the approved bi- or quadri-valent vaccines. J. Med. Virol. 88:1989-1998, 2016. © 2016 Wiley Periodicals, Inc.
authors.affiliation: Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control (NIFDC), Beijing, China.
authors.forename: Jianhui
authors.initials: J
authors.lastname: Nie
authors.affiliation: Virus Laboratory, The Affiliated Shengjing Hospital, China Medical University, Shenyang, China.
authors.forename: Jianhua
authors.initials: J
authors.lastname: Liu
authors.affiliation: Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control (NIFDC), Beijing, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Xie
authors.affiliation: Virus Laboratory, The Affiliated Shengjing Hospital, China Medical University, Shenyang, China.
authors.forename: Zhengrong
authors.initials: Z
authors.lastname: Sun
authors.affiliation: Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control (NIFDC), Beijing, China.
authors.forename: Juan
authors.initials: J
authors.lastname: Zhao
authors.affiliation: Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control (NIFDC), Beijing, China.
authors.forename: Qingqing
authors.initials: Q
authors.lastname: Chen
authors.affiliation: Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control (NIFDC), Beijing, China.
authors.forename: Yangyang
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control (NIFDC), Beijing, China.
authors.forename: Weijin
authors.initials: W
authors.lastname: Huang
authors.affiliation: Virus Laboratory, The Affiliated Shengjing Hospital, China Medical University, Shenyang, China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Ruan
authors.affiliation: Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control (NIFDC), Beijing, China.
authors.forename: Youchun
authors.initials: Y
authors.lastname: Wang
mesh_terms: D000328:Adult; D000554:Ambulatory Care Facilities / Q000706:statistics & numerical data; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood / Q000235:genetics; D002681:China / Q000453:epidemiology; D060085:Coinfection / Q000150:complications* / Q000453:epidemiology / Q000821:virology*; D005260:Female; D005838:Genotype; D061809:Human Papillomavirus DNA Tests; D052162:Human papillomavirus 16 / Q000235:genetics / Q000276:immunology; D006801:Humans; D016017:Odds Ratio; D027383:Papillomaviridae / Q000235:genetics*; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000821:virology*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000276:immunology; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000821:virology
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D053918:Papillomavirus Vaccines
keywords: human papillomavirus; neutralization; vaccine